drugset / Trial / NCT02831361

Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)

NCT02831361

Phase 3 Completed 290 enrolled LG Life Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin alone or on insulin in combination with metformin stably for 8 weeks.

Timeline

Start
2016-10-17
Primary completion
2018-02-08
Completion
2018-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule 50 mg Oral
Background Metformin Small molecule 1000 mg